Orionis Biosciences Presents Preclinical Data on Interferon and IL-2 Targeted Cytokine Immunotherapies for Cancer

Company shared progress from its proprietary A-Kine™ platform for engineering of target-selective, cis-acting cytokine immunotherapies at 2022 PEGS Europe Protein and Antibody Engineering Summit

Data demonstrate potent single-agent anti-tumor activity of immune cell-targeted interferons and interleukin-2 through remodeling of tumor microenvironments and cancer immunity cycle in syngeneic and humanized mouse models

Orionis anticipates IND submission and start of conditionally active cytokine Phase 1 trial in 2023

BOSTON, MA, USA & GHENT, Belgium I November 14, 2022 IOrionis Biosciences, a life sciences company pioneering innovation of highly selective and tunable therapeutics for cancer and beyond, today presented preclinical data supporting its A-Kine™ platform for rational design of cis-acting immuno-cytokines at the 14th Annual PEGS Europe Protein & Antibody Engineering Summit, taking place November 14 – 16 in Barcelona, Spain. The data demonstrate potent anti-tumor activity across multiple classes of targeted cytokines.

Cytokines are powerful regulators of the immune system and attractive therapeutic effector candidates. However, their sites of action must be restricted to avoid systemic toxicity. To achieve spatial control of cytokine bioactivity, Orionis has developed a proprietary biologics platform that integrates a strategic “plug-and-play” assembly of modular biomolecular building blocks into therapeutic agents with unique conditional effector functions and cell-target selectivity. These conditionally active, cis-acting cytokines aim to trigger anti-tumor immune responses even in cold tumors that lack prevalent immune involvement and are refractory to checkpoint inhibitor and other therapies.

“Today we shared preclinical data that represent exciting progress for our proprietary A-Kine platform. Our R&D engine, inspired by nature’s intrinsic mechanisms for disease control, has the potential to address some of the biggest challenges in oncology drug discovery and beyond,” said Nikolai Kley, Ph.D., Founder, President and Chief Executive Officer of Orionis Biosciences. “As we look ahead, we anticipate IND submission and the start of a conditionally active cytokine Phase 1 trial in 2023.”

Orionis’ deep and diversified A-Kine pipeline comprises multiple cytokine classes, including re-engineered interferons (IFNs), interleukins (ILs) and tumor necrosis factors (TNFs). In conjunction with an arsenal of cell-targeting strategies, Orionis is harnessing the therapeutic potential of these cytokines to reprogram immune cells and reactivate the cancer immunity cycle, and thereby the immune system’s natural mechanisms of disease control.

The company presented its advances and breakthroughs in design, engineering and development of exquisitely target-selective A-Kines incorporating:

  • Cis-acting Interferons to promote immune system recognition and infiltration of tumors
  • Cis-acting Interleukin-2 to directly activate CD8+ tumor cytotoxic T cells

These unique agents exhibit potent, single agent anti-tumor activity in multiple preclinical cancer models, mediated by targeting of key immune cells, including subtypes of myeloid cells and tumor cytotoxic CD8+ T cells, and PD-1/PD-L1 checkpoint mechanisms. Orionis’ A-Kine pipeline reflects multiple protein engineering innovations and contains an array of programs in lead optimization and IND-enabling phases.

Details of today’s presentation are as follows:

14th Annual PEGS Europe Protein & Antibody Engineering Summit, November 14–16, 2022, Barcelona, Spain

  • Title: A-Kine Platform: On-Target Cytokines to Reprogram Cell Targets for Immuno-Oncology
  • Date and Time: Monday, November 14, 11:45 a.m. CET
  • Presenter: Erik Depla, Ph.D., Director of Biology, Orionis Bio

Orionis recently announced a $55 million financing to support entry of its lead A-Kine cancer immunotherapy programs into the clinic. The company anticipates IND submission and start of a Phase 1 study of a conditionally active cytokine in 2023. In addition to the A-Kine platform, Orionis has developed the Allo-Glue™ protein degradation platform for discovery and rational design of small molecule molecular glues. These types of conditionally active small molecules are designed to tackle traditionally undruggable or elusive drug targets by harnessing nature’s cellular machinery to degrade and dispose of proteins that cause and/or promote disease.

About Orionis Biosciences
Orionis Biosciences is a life sciences company pioneering technological innovations in genome-scale drug discovery to develop novel, highly specific and tunable therapeutics for cancer and beyond. The company utilizes its proprietary A-Kine™ biologics and Allo-Glue™ small molecule platforms to target core disease vulnerabilities and reach previously intractable targets. Orionis has multiple first-in-class immunotherapies in development for the treatment of cancer. Learn more at www.orionisbio.com.

SOURCE: Orionis Biosciences

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2021 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up

Top